Skip to main content
SpringerLink
Log in

Congenital Adrenal Hyperplasia

  • Chapter
Pediatric Endocrinology

Part of the book series: Contemporary Endocrinology ((COE))

  • 273 Accesses

Abstract

Congenital adrenal hyperplasia (CAH) is a family of autosomal recessive disorders in which there is a deficiency of one of the enzymes necessary for cortisol synthesis (1) (see Fig. 1). An abnormality in each of the enzymatic activities required for cortisol synthesis has been described. As a result of the disordered enzymatic step, there is decreased cortisol synthesis, increased ACTH via the negative feedback system, overproduction of the hormones prior to the enzymatic step or not requiring the deficient enzyme, and deficiency of the hormones distal to the disordered enzymatic step. Since certain of the enzymatic steps are required for sex hormone synthesis by the gonad, a disordered enzymatic step in the gonad, resulting in gonadal steroid hormone deficiency, may also be present (2).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 74.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Levine LS. Congenital adrenal hyperplasia. Pediatr Rev 2000; 21: 159–170.

    Article  PubMed  CAS  Google Scholar 

  2. Grumbach MM, Conte FA. Disorders of sex differentiation. In: Wilson JD, ed. Williams Textbook of Endocrinology, 9th ed. Saunders, Philadelphia. 1998, pp. 1361–1374.

    Google Scholar 

  3. Pang S. Congenital adrenal hyperplasia. Endocrinol Mctab Clin North Am 1997; 26: 853–891.

    Article  CAS  Google Scholar 

  4. Miller WL. Molecular biology of steroid hormone synthesis. Endocr Rev 1998; 9: 295–318.

    Article  Google Scholar 

  5. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000; 21: 245–291.

    Article  PubMed  CAS  Google Scholar 

  6. New MI. Diagnosis and management of congenital adrenal hyperplasia. Ann Rev Med 1998; 49: 311–328.

    Article  PubMed  CAS  Google Scholar 

  7. Bose HS, Sugawara T, Strauss III JF, et al. The pathophysiology and genetics of congenital lipoid adrenal hyperplasia. N Engl J Med 1996; 355: 1870–1878.

    Article  Google Scholar 

  8. Miller WL. Congenital lipoid adrenal hyperplasia: The human gene knockout for the steroidogenic acute regulatory protein. J Mol Endocrinol 1997; 19: 227–240.

    Article  PubMed  CAS  Google Scholar 

  9. Fujieda K, Tajima T, Nakae J, et al. Spontaneous puberty in 46,XX subjects with congenital lipoid adrenal hyperplasia. J Clin Invest 1997: 99: 1265–1271.

    Article  PubMed  CAS  Google Scholar 

  10. Bose HS, Sato S, Aisenberg J, et al. Mutations in the steroidogenic acute regulatory protein (StAR) in six patients with congenital lipoid adrenal hyperplasia. J Clin Endocrinol Metab 2000; 85: 3636–3639.

    Article  PubMed  CAS  Google Scholar 

  11. Tajima T, Fujieda K, Kouda N, et al. Heterozygous mutation in the cholesterol side chain cleavage enzyme (P450scc) gene in a patient with 46,XY sex reversal and adrenal insufficiency. J Clin Endocrinol Mctab 2001; 86: 3820–3825.

    Article  CAS  Google Scholar 

  12. Katsumata N, Ohtake M, Hojo T, et al. Compound heterozygous mutations in the cholesterol side-chain cleavage enzyme gene (CYP11A) cause congenital adrenal insufficiency in humans. J Clin Endocrinol Metab 2002; 87: 3808–3813.

    Article  PubMed  CAS  Google Scholar 

  13. Simard J, Rhéaume E, Sanchez R, et al. Molecular basis of congenital adrenal hyperplasia due to 33-hydroxysteroid deficiency. Mol Endocrinol 1993; 7: 71. 6–728.

    Google Scholar 

  14. Mason JI. The 33-hydroxysteroid dehydrogenase gene family of enzymes. Trends Endocrinol Metab 1993; 6: 199.

    Google Scholar 

  15. Chang YT, Zhang L. Alkaddour HS, et al. Absence of molecular defect in the Type II 33-hydroxysteroid dehydrogenase (313-HSD) gene in premature pubarche children and hirsute female patients with moderately decreased adrenal 3J3-HSD activity. Pediatr Res 1995; 37: 820–824.

    Article  PubMed  CAS  Google Scholar 

  16. Pang S. Genetics of 343-hydroxystcroid dehydrogenase deficiency disorder. Growth Genet Horm 1996; 12: 5–9.

    Google Scholar 

  17. Moison AM, Ricketts ML, Tardy V, eeal. New insight into the molecular basis of 33-hydroxysteroid dehydrogenase deficiency: Identification of eight mutations in the HSD3B2 gene in eleven patients from seven new families and comparison of the functional properties of twenty-five mutant enzymes. J Clin Endocrinol Metab 1999; 84: 4410–4425.

    Article  Google Scholar 

  18. Marui S, Castro M, Latronico AC, et al. Mutations in the type II 33-hycloxysteroid dehydrogenase (HSD3B2) gene can cause premature pubarche in girls. Clin Endocrinol 2000; 52: 67–75.

    Article  CAS  Google Scholar 

  19. Yanase T, Simpson ER, Waterman MR. 17a-hydroxylase/17,20-lyase deficiency: From clinical investigation to molecular definition. Endocr Rev 1991; 12: 91–108.

    CAS  Google Scholar 

  20. Zachmann M. Prismatic cases: 17,10-desmolase (17,20-lyase) deficiency. Clin Endocrinol 1996; 81: 457–459.

    Article  CAS  Google Scholar 

  21. Geller DH, Auchus RJ, Mendonca BB, et al. The genetic and functional basis of isolated 17,20-lyase deficiency. Nat Genet 1997; 17: 201–205.

    Article  PubMed  CAS  Google Scholar 

  22. Geley S, Kapelari K, Jöhrer K, et al. CYP11B1 mutations causing congenital adrenal hyperplasia due to 113-hydroxylase deficiency. J Clin Endocrinol Metab 1996; 81: 2896–2901.

    Article  PubMed  CAS  Google Scholar 

  23. White PC, Curnow KC, Pascoe L. Disorders of steroid 110-hydroxylase isozymes. Endocr Rev 1994;15: 421.-438.

    Google Scholar 

  24. Merke DP, Tajima T, Chhabra A, et al. Novel CYP 11 B I mutations in congenital adrenal hyperplasia due to steroid 113-hydroxylase deficiency. J Clin Endocrinol Metab 1998; 83: 270–273.

    Article  PubMed  CAS  Google Scholar 

  25. Zachmann M, Tassinari D, Prader A. Clinical and biochemical variability of congenital adrenal hyperplasia due 113-hydroxylase deficiency: A study of 25 patients. J Clin Endocrinol Metab 1983; 56: 222–229.

    Article  PubMed  CAS  Google Scholar 

  26. Rivkees SA, Crawford JD. Dexamethasone treatment of virilizing congenital adrenal hyperplasia: The ability to achieve normal growth. Pediatrics 2000; 106: 767–773.

    Article  PubMed  CAS  Google Scholar 

  27. Schober JM. Feminizing genitoplasty for intersex. In: Stringer MD, Oldham KT, and Moriquand PDE, and Howard BR eds. Pediatric surgery and urology: Long term outcomes. Saunders, Philadelphia, 1998, pp. 549–558.

    Google Scholar 

  28. Meyer-Bahlburg HFL. What causes low rates of child-bearing in congenital adrenal hyperplasia? J Clin Endocrinol Metab 1999: 84: 1844–1847.

    Article  PubMed  CAS  Google Scholar 

  29. Alizai NK, Thomas DFM, Lilford TRJ, Batchelor AGG, Johnson N Feminizing genitoplasty for congenital adrenal hyperplasia: What happens at puberty? J Urol 1999;161: 1588-•1591.

    Google Scholar 

  30. Krege S, Walz KH, Hauffa BP, et al. Long-term follow-up of female patients with congenital adrenal hyperplasia from 21-hydroxylase deficiency, with special emphasis on the results of vaginoplasty. BJU Int 2000;86: 253–259

    Google Scholar 

  31. Soliman AT, AlLamki M, AlSalmi I, et al. Congenital adrenal hyperplasia complicated by central precocious puberty: linear growth during infancy and treatment with gonadotropin-releasing hormone analog. Metab, 1997; 46: 513–517.

    Article  CAS  Google Scholar 

  32. Laue L, Merke SP, Jones JV, et al. A preliminary study of flutamide, testolactone, and reduced hydrocortisone dose in the treatment of congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81: 3535–3539.

    Article  PubMed  CAS  Google Scholar 

  33. Merke DP, Keil MF, Jones JV, et al. Flutamide, testolactone, and reduced hydrocortisone dose maintain normal growth velocity and bone maturation despite elevated androgen levels in children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2000;85: 11I4–1120.

    Google Scholar 

  34. Alvi S, Shaw NJ, Rayner PHW, et al. Growth hormone and goserelin in congenital adrenal hyperplasia. Holm Res 1997;48(Suppl 2): l-201.

    Google Scholar 

  35. Quintos JB, Vogiatzi MG, Harbison MD, et al. Growth hormone and depot leuprolidc therapy for short stature in children with congenital adrenal hyperplasia. Annual Meeting Endocrine Society 1999. Program & Abstracts: 1I0.

    Google Scholar 

  36. Van Wyk JJ, Gunther DF, Ritzen EM, et al. Therapeutic Controversies: The use of adrenalectomy as a treatment for congenital adrenal hyperplasia. J Clin Endocrinol Metab 1996; 81: 3180–3190.

    Article  PubMed  Google Scholar 

  37. Gunther DF, Bukowski TP, Titzen EM, et al. Prophylactic adrenalectomy of a three-year-old girl with congenital adrenal hyperplasia: Pre-and postoperative studies. J Clin Endocrinol Metab 1997; 82: 3324–3327.

    Article  PubMed  CAS  Google Scholar 

  38. Nasir J, Royston C, Walton C, et al. 11f3-hydroxylase deficiency: Management of a difficult case by laparoscopie bilateral adrenalectomy. Clin. Endocrinol 1996; 45: 225–228.

    Article  CAS  Google Scholar 

  39. Chabre O. Portrat-Doyen S, Chaffanjon P, et al. Bilateral laparoscopie adrenalectomy for congenital adrenal hyperplasia with severe hypertension, resulting from two novel mutations in splice donor sites of CYPi 1B1. J Clin Endocrinol Metab 2000; 85: 4060–4068.

    Article  PubMed  Google Scholar 

  40. Lo JC, Schwitzgebel VM, Tyrrell JB, et al. Normal female infants horn of mothers with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 1999; 84: 930–936.

    Article  PubMed  CAS  Google Scholar 

  41. Lim YJ, Batch JA, Warne GL. Adrenal 21-hydroxylase deficiency in childhood: 25 years’ experience. J Paediatr Child Health 1995; 31: 222–227.

    Article  PubMed  CAS  Google Scholar 

  42. Rasat R, Espiner EA, Abbott GD. Growth patterns and outcomes in congenital adrenal hyperplasia: Effect of chronic treatment regimes. NZ Med J 1995; 108: 311–314.

    CAS  Google Scholar 

  43. Yu ACM, Grant DB. Adult height in women with early-treated congenital adrenal hyperplasia (21-hydroxylase type): Relation to body mass index in earlier childhood. Acta Päediatr 1995; 84: 899–903.

    Article  PubMed  CAS  Google Scholar 

  44. Hauffa BP, Winter A, Stolecke H. Treatment and disease effects on short-term growth and adult height in children and adolescents with 21-hydroxylase deficiency. Klin Padiatr 1997; 209: 71–77.

    Article  PubMed  CAS  Google Scholar 

  45. Jaaskelainen J, Voutilainen R. Growth of patients with 21-hydroxylase deficiency: An analysis of the factors influencing adult height. Pediatr Res 1997; 41: 30–33.

    Article  PubMed  CAS  Google Scholar 

  46. Kandemir N, YordamN. Congenital adrenal hyperplasia in Turkey: A review of 273 patients. Acta Paediatr 1997; 86: 22–25.

    Google Scholar 

  47. Kuhnle U, B ullinger M. Outcome of congenital adrenal hyperplasia. Pediatr Surg Int 1997; 12: 511–515.

    Article  PubMed  CAS  Google Scholar 

  48. Premawardhana LDKE, Hughes IA, Read GH, et al. Longer term outcome in females with congenital adrenal hyperplasia (CAH): The Cardiff experience. Clin Endocrinol 1997; 46: 327–332.

    Article  CAS  Google Scholar 

  49. Eugster EA, DiMeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: A meta-analysis. J Pediatr 2001; 138: 26–32.

    CAS  Google Scholar 

  50. Schwartz RP. Back to basics: Early diagnosis and compliance improve final height outcome in congenital adrenal hyperplasia. J Pediatr 2001; 138: 3–5.

    Article  PubMed  CAS  Google Scholar 

  51. Diamond M. Prenatal predisposition and the clinical management of some pediatric conditions. J Sex Marital ‘Ter 1996; 22: 139.

    Article  CAS  Google Scholar 

  52. Diamond M, Sigmundson HK. Sex reassignment at birth. Arch Pediatr Adolesc 1997; 151: 298.

    Article  CAS  Google Scholar 

  53. Hagenfeldt K, Ritzen EM, Ringertz H, et. al. Bone mass and body composition of adult women with congenital virilizing 21-hydroxylase deficiency after glucocorticoid treatment since infancy. Eur i Endocrinol 2000; 143: 667–671.

    Article  CAS  Google Scholar 

  54. Forest MG, Morel Y, David M. Prenatal treatment of congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency. Frontiers Endocrinol 1996; 17: 77–89.

    Google Scholar 

  55. Carlson AD, Obeid JS. Kanellopoulou N, et al. Congenital adrenal hyperplasia: Update on prenatal diagnosis and treatment..1 Steroid Biochem Mol Biol 1999; 69: 19–29.

    Article  CAS  Google Scholar 

  56. Rosier A, Weshler N, Leiberman E, et at. 1113-hydroxylase deficiency congenital adrenal hyperplasia: Update of prenatal diagnosis. J Clin Endocrinol Metab 1988; 66: 830–838.

    Article  Google Scholar 

  57. Ccrame BI, Newfield RS, Pascoe L, et al. Prenatal diagnosis and treatment of 1113-hydroxylase deficiency congenital adrenal hyperplasia resulting in normal female genitalia. J Clin Endocrinol Metab 1999; 84: 3129–3134.

    Article  Google Scholar 

  58. Izumi H, Saito N, Ichiki S, et al. Prenatal diagnosis of congenital lipoid adrenal hyperplasia. Obstet Gynecol 1993; 81: 839–841.

    PubMed  CAS  Google Scholar 

  59. Saenger P. New developments in congenital lipoid adrenal hyperplasia and steroidogenic acute regulatory protein. Pediatr Clin North Am 1997; 44: 397–421.

    Article  PubMed  CAS  Google Scholar 

  60. David M, Forest MG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency..1 Pediatr 1984; 105: 799–803.

    Google Scholar 

  61. Levine LS, Pang S Prenatal diagnosis and treatment of congenital adrenal hyperplasi a. In: Milunsky A, ed. Genetic disorders and the fetus: Diagnosis, prevention and treatment. Fourth edition. The Johns Hopkins University Press, Baltimore, 1998, pp. 529–549.

    Google Scholar 

  62. Pang S, Clark AT, Freeman LC, et al. Maternal side effects of prenatal dexamethasone therapy for fetal congenital adrenal hyperplasia. J Clin Endocrinol Metab 1992; 75: 249–253.

    Article  PubMed  CAS  Google Scholar 

  63. Forest MG, Don HG. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency: European experience in 253 pregnancies at risk. Clin Cour 1.993;11: 2. 3.

    Google Scholar 

  64. Lajic S, Wedell A, Bui T, et al. Long-term somatic follow-up of prenatally treated children with congenital adrenal hyperplasia. J Clin Endocrinol Metab 1998;83: 3872–3880

    Google Scholar 

  65. Trautman PD, Meyer-Bahlburg HFL, Postelnek J, et al. Effects of early prenatal dexamethasone on the cognitive and behavioral development of young children: Results of a pilot study. Psychoneuroendocrinology 1995; 20: 439–449.

    Article  PubMed  CAS  Google Scholar 

  66. Forest MG, Morel Y, David M. Prenatal treatment of congenital adrenal hyperplasia. Trends Endocrinol Metab 1998; 9: 284–288.

    Article  PubMed  CAS  Google Scholar 

  67. Trautman PD, Meyer-Bahlburg HF, Postelnek J, et al. Mothers’ reactions to prenatal diagnostic procedures and dexamethasone treatment of congenital adrenal hyperplasia. J Psychosom Obstet Gynaecol 1996; 17: 175–181.

    Article  PubMed  CAS  Google Scholar 

  68. Miller WL. Prenatal treatment of congenital adrenal hyperplasia: A promising experimental therapy of unproven safety. Trends Endoçrinol Metab 1998; 9: 290–293.

    Article  CAS  Google Scholar 

  69. Pang S, Hotchkiss J, Drash AL, et al. Microfilter paper method for 17a-hydroxyprogesterone radio-immunoassay; its application for rapid screening for congenital adrenal hyperplasia. J Clin Endocrinol Metah 1977; 45. 1003–1008.

    Article  CAS  Google Scholar 

  70. Pang S, M urphey W, Levine LS, et al. A pilot newborn screening for congenital adrenal hyperplasia in Alaska. J Clin Endocrinol Metab 1982; 55: 413–420.

    Article  PubMed  CAS  Google Scholar 

  71. Pang S, Wallace MA, Hofman L, et al. Worldwide experience in newborn screening for classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Pediatrics 1988; 81: 866–874.

    PubMed  CAS  Google Scholar 

  72. Pang S, Clark A. Congenital adrenal hyperplasia due to2l-hydroxylase deficiency: Newborn screening and its relationship to the diagnosis and treatment of the disorder. Screening 1993; 2: 105–139.

    Article  Google Scholar 

  73. Balsamo A, Cacciari E, Piazzi S, et al. Congenital adrenal hyperplasia: Neonatal mass screening compared with clinical diagnosis only in the Emilia-Romagna region of Italy. Pediatrics 1996; 98: 362–367.

    PubMed  CAS  Google Scholar 

  74. Cutfield WS, Webster D. Newborn screening for congenital adrenal hyperplasia in New Zealand. J Pediatr 1.995; 126: 118–121.

    Google Scholar 

  75. Dotti G, Pagliardini S, Vuolo A, et al. Congenital adrenal hyperplasia in the experience of the Piemonte and Valle d’ Aosta regions program (1987–1995). In: Programs & Abstracts of the 3rd International Newborn Screening Meeting, Oct.22–23, 1996 Boston, MA USA. Abstract No.P-82.

    Google Scholar 

  76. Nordenstrom A, Thilen A, Hagenfeldt L, et al. Benefits of screening for congenital adrenal hyperplasia (CAH) in Sweden. In: Proceedings, Third Meeting of the International Society for Neonatal Screening, Levy HL, Hermos RJ, Grady GF, eds. Oct.22–23, 1996 Boston, MA USA. P: 211–216.

    Google Scholar 

  77. Sack J, Front H, Kaiserman 1, et al. Screening for 21-hydroxylase deficiency in Israel. In: Programs & Abstracts of the 3rd International Newborn Screening Meeting, Oct.22–23, 1996 Boston, MA USA. Abstract No. P-87.

    Google Scholar 

  78. Al-Nuaim AA. Newborn screening program (NSP) in Saudi Arabia (SA), In: Programs & Abstracts of the 3rd International Newborn Screening Meeting, Oct.22–23, 1996 Boston, MA USA. Abstract No.P-90.

    Google Scholar 

  79. Pang S, Shook M. Current status of neonatal screening for congenital adrenal hyperplasia. Curr Opin Pediatr 1997; 9: 419–423.

    Article  PubMed  CAS  Google Scholar 

  80. Tajima T, Fujieda K, Nakae J, et al. Molecular basis of nonclassical steroid 21-hydroxylase deficiency detected by neonatal mass screening in Japan. J Clin Endocrinol Metab 1997; 82: 2350–2356.

    Article  PubMed  CAS  Google Scholar 

  81. herrel BL Jr. Berenbaum SA, Manter-Kapanke V, et al. Results of screening 1.9 million Texas newborns for 21-hydroxylase-deficient congenital adrenal hyperplasia. Pediatrics 1998; 101: 583–590.

    Article  PubMed  Google Scholar 

  82. Allen DB, Hoffman GL, Mahy SL, et al. Improved precision of newborn screening for congenital adrenal hyperplasia using weight adjusted criteria for 17-hydroxyprogesterone levels. J Pediatr 1997; 130: 120–133.

    Google Scholar 

  83. Brosnan PG, Brosnan CA, Kemp SF, et al. Effect of newborn screening for congenital adrenal hyperplasia. Arch Pediatr Adolesc Med 1999; 153: 1272–1278.

    PubMed  CAS  Google Scholar 

  84. Kwon C, Farrell PM. The magnitude and challenge of false-positive newborn screening test results. Arch Pediatr Adolesc Med 2000; 154: 714–718.

    PubMed  CAS  Google Scholar 

  85. Adapted from Miller WL, Levine LS. Molecular and clinical advances in congenital adrenal hyperplasi a. J Pediatr 1987; 111: 1.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. Lenore S. Levine MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Sharon E. Oberfield MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Section of Pediatric Endocrinology, University of Chicago Medical Center, Chicago, IL, USA

    Sally Radovick MD

  2. Division of Endocrinology, Children’s Hospital of Buffalo, Buffalo, NY, USA

    Margaret H. MacGillivray MD

Rights and permissions

Reprints and permissions

Copyright information

© 2003 Springer Science+Business Media New York

About this chapter

Cite this chapter

Levine, L.S., Oberfield, S.E. (2003). Congenital Adrenal Hyperplasia. In: Radovick, S., MacGillivray, M.H. (eds) Pediatric Endocrinology. Contemporary Endocrinology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-336-1_13

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-336-1_13

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61737-268-1

  • Online ISBN: 978-1-59259-336-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation